Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) - Total Liabilities
Based on the latest financial reports, Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) has total liabilities worth $9.14 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Drugs Made In America Acquisition Corp. short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Drugs Made In America Acquisition Corp. Ordinary Shares - Total Liabilities Trend (2024–2025)
This chart illustrates how Drugs Made In America Acquisition Corp. Ordinary Shares's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see total assets of Drugs Made In America Acquisition Corp. .
Drugs Made In America Acquisition Corp. Ordinary Shares Competitors by Total Liabilities
The table below lists competitors of Drugs Made In America Acquisition Corp. Ordinary Shares ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Odfjell Technology Ltd
OL:OTL
|
Norway | Nkr3.01 Billion |
|
Shenzhen Ecobeauty Co Ltd
SHE:000010
|
China | CN¥2.25 Billion |
|
Bonduelle S.C.A.
PA:BON
|
France | €1.47 Billion |
|
HomeStreet Inc
NASDAQ:HMST
|
USA | $7.21 Billion |
|
PRG Corporation Public Company Limited
BK:PRG
|
Thailand | ฿2.31 Billion |
|
Federal Corp
TW:2102
|
Taiwan | NT$6.89 Billion |
|
Space Asset Acquisition Corp. Class A Ordinary Shares
NASDAQ:SAAQ
|
USA | $90.06K |
|
Com2uS Corporation
KQ:078340
|
Korea | ₩509.34 Billion |
Liability Composition Analysis (2024–2025)
This chart breaks down Drugs Made In America Acquisition Corp. Ordinary Shares's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See how leveraged is Drugs Made In America Acquisition Corp. 's balance sheet to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.02 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Drugs Made In America Acquisition Corp. Ordinary Shares's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Drugs Made In America Acquisition Corp. Ordinary Shares (2024–2025)
The table below shows the annual total liabilities of Drugs Made In America Acquisition Corp. Ordinary Shares from 2024 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $7.28 Million | +914371.07% |
| 2024-12-31 | $795.67 | -- |
About Drugs Made In America Acquisition Corp. Ordinary Shares
Drugs Made In America Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combinations with one or more businesses. Drugs Made In America Acquisition Corp. was incorporated in 2024 and is based in New York, New York.